Heart valve bioprostheses of the "Bionix" series. 6-year experience with the mitral valve replacement

• Published in: Grudnaia i serdechno-sosudistaia khirurgiia no. 10; p. 11
• Main Authors: Fursov, B A, Zaĭtsev, V V, Bykova, V A, Mishchenko, B P, Gorshkov, Iu V, Svanidze, O G, Evdokimov, S V, ZaĭtsevLV, Rusanov, N I, Tsukerman, G I
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01-10-1991
• Subjects: Adult; Aged; Animals; Bioprosthesis; Calcinosis - complications; Calcinosis - physiopathology; Calcinosis - surgery; Equipment Design; Female; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valve - physiopathology; Mitral Valve - surgery; Mitral Valve Stenosis - etiology; Mitral Valve Stenosis - physiopathology; Mitral Valve Stenosis - surgery; Postoperative Period; Swine; Time Factors; USSR; USSR
• ISSN: 0236-2791

The main cause of cardiac valve bioprosthesis dysfunction is mechanical rupture of the cusps consequent upon the development of "fatigue" tensions and calcification of the biologic tissue. The technology of "Bionix" prostheses manufacturing implies prevention of these complications by means of supporting frameworks of variable rigidity (dumping stroke loads) and the use of a calcinosis inhibitor in the process of chemical stabilization. Experimental research confirms the certain effectiveness of such an approach to solving the problem of bioprosthesis durability. Experience in clinical application of biological valves of this series showed that by the 5th postoperative year the stability of good results was 90.0 +/- 2.2%; absence of thromboembolic complications in 93.3 +/- 2.4%, and no need to operate because of dysfunction of the bioprosthesis in 96.6 +/- 2.1%.